Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The...
A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...